Home News

San Antonio, USA, September 15th 2014. Keraplast announced today that a $1.6M grant had been awarded to the research institute AgResearch for a programme of research focused on keratin based wound care. The four year programme, led by senior scientist Dr Stefan Clerens from the Proteins and Biomaterials Team will extend knowledge of the bioactive performance of keratin proteins in a wound healing environment leading to the development of more advanced and higher performance keratin wound care devices to better address unmet clinical needs in wound care.

Keraplast Technologies is the commercial partner in the programme and collaborators include scientists from the University of Miami Miller School of Medicine.

Dr Rob Kelly, Keraplast Technologies Chief Scientific Officer and Interim Chief Executive Officer said “As the only company with keratin based wound care products in the market and in use in clinics around the world we are excited to be partnering with AgResearch in this scientific programme. We have consistently been at the forefront of keratin science and have a demonstrated track record of transforming that science into clinical benefits to make a difference to the lives of patients with unmet needs in wound care. This groundbreaking research from a world class team will ensure we maintain our position at the leading edge of applying keratin science in medicine.”

Dr Sonya Scott, key senior scientist in the programme, said “This is extremely exciting research, as it is a combinations of insight in biological modes of action and direct commercial application with real health outcomes. A core strength of AgResearch is the translation of excellent science into commercial outcomes, and working with the Keraplast team, and our collaborators at the University of Miami, will ensure that continues.”

Dr Stefan Clerens, Science Team Leader in the Proteins and Biomaterials Team added “The Protein and Biomaterials Team is world class in the field of keratin science and proteomics. Gaining the support from the government recognizes that expertise and gives us the foundation to further elucidate the biological mechanisms and performance of keratin proteins and peptides.”

The grant has been awarded under the High-Value Manufacturing and Services Research Fund as part of the Ministry of Business, Innovation & Employment and is for research commencing in October 2014.

For more information contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it or This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Posted in Company News |

San Antonio, USA, July 10th 2014. Keraplast Technologies announced today that following evaluation at the specialist epidermolysis bullosa clinic at Great Ormond Street Hospital in London under the supervision of leading DEBRA Nurse Jackie Denyer, the keratin wound care gel keragelT® has been placed on the UK drug tariff list. This means clinicians and carers in the UK can now choose keragelT®, the latest tool for EB wound management, and have confidence that the care will be funded by the NHS.

In addition, H&R Healthcare has been appointed as UK distributor for the Keraplast wound care product range, including the keratin based products keragelT®, keragel®, keramatrix® and kerasorb®. This means that the only keratin based wound care products on the market are now available through the leading supplier of specialist wound care innovations in the UK.

Dr Rob Kelly, Interim Chief Executive Officers of Keraplast Technologies said “The unique approach to wound care that Replicine Functional Keratin provides is clearly solving unmet clinical needs in several disciplines, leading to growing interest in Europe. We are very pleased to be able to make a difference in the management epidermolysis bullosa and work closely with specialist clinics such as Great Ormond Street Hospital in London and EB Haus in Austria. Having keragelT® funded on the UK Drug Tariff will make a significant difference to families in the UK living with EB as they now have the latest advancement available to them. We are also seeing strong interest from groups working at the forefront of chronic wound care, such as the pressure ulcer group at Stoke Mandeville hospital who recently presented work on keragel® and keramatrix® at the 16th National Congress on Paraplegic Medicine in Italy.” He added “partnering with H&R Healthcare is perfect for us as they are clearly well recognised as being specialists at bringing wound care innovations into the UK healthcare system and we share the common goal of using innovation to improving patient outcomes.”

Mike Hoskins, Chief Executive Officer of H&R Healthcare said “our philosophy is

to offer innovative products that give the best overall value to the NHS, measured by patient outcomes and overall cost effectiveness. The Keraplast product range clearly provides this and we are excited about introducing this innovation to the UK.”

For product enquires from the UK please contact H&R Healthcare Ltd, Tel: +44 (0)1482 631606, Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it , web http://www.hrhealthcare.co.uk/index.html

Posted in Company News |

Replicine™ Functional Keratin® advanced wound care technology is now available in Denmark, Norway and Sweden following appointment of Med-Vice (Denmark and Norway) and MedPre AB (Sweden) as distributors of Keraplast wound care products.

Dr Rob Kelly, Interim Chief Executive of Keraplast said “health care in Scandinavia is well recognized as among the best in the world. The improved clinical outcomes available using Replicine Functional Keratin wound care products, in particular in management of epidermolysis bullosa, but also in care for chronic wounds and burns, is creating demand from clinicians in these regions that are used to providing their patients the best care available. We are pleased to have found local partners that are respected by the health care community and understand well how to get the best care to patients as easily as possible.”

Marie Louise Little, CEO of Med-Vice said “Interest in keragelT from the epidermolysis bullosa community is very high in many parts of Europe, including Denmark and Norway. Local clinicians always want to offer the best care, in particular to those in most need such as families living with EB and we are excited to now have that option available”

Magnus Precht, CEO of MedPre said “Replicine Functional Keratin is truly innovative and is well supported with published clinical data. It complements well the other advanced innovation that Med Pre offers to the wound care community and we are already seeing strong interest from the clinical community”

For enquires from Denmark or Norway contact Med-Vice on +45 4576 7626, www.med-vice.com or This e-mail address is being protected from spambots. You need JavaScript enabled to view it

For enquiries from Sweden contact MedPre AB on +46-708-205041 or at www.medpre.se.

Posted in Company News |

Over the last 12 months 5 new peer review papers were published on clinical outcomes of Replicine Functional Keratin wound care products. These included randomized controlled studies of scar healing and donor site healing, as well as a case series study of chronic wounds. These peer review publications are in addition to 9 conference presentations in the same period and consolidate the substantial evidence base supporting clinical use of Replicine Functional Keratin wound care products to manage a wide range of wound types.

Dr Robert Allen Smith, Medical Director of Keraplast Technologies said “Evidence based practice underpins the clinical choices made in wound care. Peer review science is the gold standard for establishing the required evidence base, and as a result of the increasing evidence base for Replicine Functional Keratin, clinicians around the world are embracing keratin as the treatment method of choice.”

Dr Rob Kelly, Chief Scientific Officer of Keraplast Technologies added “The fact that Replicine Functional Keratin wound care products are established in markets around the world with the necessary regulatory approvals and a growing distribution network means that making a good, evidence based decision to manage wounds using keragel, keramatrix or kerasorb, is getting easier and easier. From managing the severe skin disorder epidermolysis bullosa to improving outcomes for chronic wounds, burns, or reducing scars, the clinical decisions being made to use Replicine Functional Keratin are backed by published data.”

The latest publications on Replicine Functional Keratin wound care are listed here: http://www.keraplast.com/evidence-based-wound-care

Keraplast Technologies will be discussing the latest clinical findings on keratin wound care with forward thinking clinicians at the SAWC convention in Orlando, Florida, April 24-26 2014 and the European Wound Management Association (EWMA) conference in Madrid May 14-16 2014

Posted in Company News |

The latest clinical research in the treatment of burns, diabetic foot ulcers, chronic venous ulcers and surgical wounds using keratin protein technology will all be showcased at spring SAWC, Denver May 1-5 2013.

Replicine™ Functional Keratin® wound care is rapidly becoming established as the treatment of choice at forward thinking hospitals and wound centers across the US. Thought leading physicians from several US facilities will present their latest findings on keratin wound care in a series of poster presentations. Further details on keratin wound care developments and how Replicine™ Functional Keratin® can improve your patient outcomes and reduce cost of care can be found by visiting Keraplast Technologies at booth 546, or by viewing the following posters at the conference.

Use of keratin gel technology to speed healing of hard to heal wounds.K. Nicki Blasiole MSN, RN, CWOCN, Elliot Mostow MD, MPH
Akron General Medical Center, Wound Healing and Limb Preservation Center
CS-009

The Use of Keratin Dressings in the Treatment of Venous Ulcers
Terry Treadwell, MD, FACS, Donna Walker, LPN, Betty Jean Nicholson, CNA, Maggie Taylor, NA
Institute for Advanced Wound Care, Montgomery, Alabama
CS-0127

Keratin dressings for effective wound care management in acute superficial and partial thickness burn injuries
Dr Fiona Loan, Dr Clive Marsh, Mrs Sharon Cassidy, Mr Jeremy Simcock
Department of Plastic and Reconstructive Surgery, Christchurch Hospital, New Zealand
CS-090

Keratin Products in the Treatment of an Unusual Acute Surgical Wound with Tendon Exposure
Virginia Capasso, PhD, ANP-BC, CWS, Massachusetts General Hospital.
CS-024

A new approach to diabetic foot ulcers using keratin gel technology
Farheen Wahid, BA, Shrunjay R. Patel, BSc, Stephanie Wu, MD. Dr. William M. Scholl College of Podiatric Medicine
Rosalind Franklin University
CS-139

A Randomised Controlled Trial of Functional Keratin Dressings for Treatment of Chronic Venous Leg Ulcers
Wen Qing Fu et al.The Medical Academy of Soochow University; Suzhou Jiangsu 215123, China.
CS-042

Posted in Company News |

SAN Antonio, USA, February 5, 2013. Keraplast technologies announced today the listing of Replicine™ Functional Keratin® wound care products on the Federal Supply Schedule (FSS). VA health care facilities and active military organizations, such as the Department of Defense, are now able to access Replicine™ Functional Keratin® wound care products through the military supplies distributor Marathon Medical.

Dr Rob Kelly, CEO of Keraplast Technologies, said “Replicine Functional Keratin is a new paradigm in wound healing, providing a significant advancement in the care chronic wounds, such as venous leg ulcers and diabetic foot ulcers, as well as acute wounds such as burns and trauma injuries. Keraplast is proud to be able to offer this advancement for the care of veterans and active military personnel.”

The products keragel™, keramatrix® and kerasorb® are available on the FSS through established supplier Marathon Medical. John St Leger, CEO of Marathon Medical said “Marathon has been serving the needs of our soldiers and veterans for 11 yrs. We strive of offer the most advanced and effective healthcare products available and the Replicine Functional Keratin advanced wound care range ensure we continue to provide the best care possible.”

For more information on accessing the products from Marathon Medical visit http://www.marathonmed.com/index.html or call 877.431.4753.

To learn more about Replicine Functional Keration wound care products visit http://www.keraplast.com/wound-care   or call 210 494 5596.

About Keraplast

Keraplast Technologies LLC, a privately held company founded in 1996, is the world’s leading developer and manufacturer of keratin products. Headquartered in San Antonio, Texas, Keraplast manufactures Replicine™ Functional Keratin® wound care products with FDA and CE mark clearance for sale around the world, as well as a wide range of skin care, hair care and nutritional solutions using proprietary keratin technology.

About Marathon Medical

Marathon Medical’s management has been in the medical supply business for over 80 years and our company has been in existence for over 11 years.  We distribute nationally with LTL and package contracts with many of the major carriers.  Please take a few minutes to visit our website, www.marathonmed.com and you will see that we are committed to the military member, the veteran and the service disabled veteran.  Since I have and do belong to each of these categories I have a serious devotion and commitment to each.  This is more than just a job to us.  You will note that on the last page of our website that we back up our words with action.  We pledge a percentage of our sales quarterly to two different veteran charities, American Freedom Foundation and the Wounded Warrior Project.

Please note that we are independently verified by The Center For Veterans Enterprise (CVE) that John St. Leger is a SDVOSB and he is 100% owner of Marathon Medical.

Posted in Company News |

PORTLAND, Oregon, USA, December 4, 2012 – There is a new face in the global effort to save rhinos from poaching. In response to U.S. Secretary of State Hillary Clinton’s call to action on Wildlife Conservation Day for a global effort to combat wildlife crime, Rhinoceros Horn LLC announced today of plans to provide an ethical alternative to rhino horn and so reduce the incentive to illegally poach rhinos. The company will fund the cause through funds raised on the popular crowd-funding site, IndieGoGo.com from December 13th and use the money to market a new ethically sourced keratin protein product to save the threatened and critically endangered rhinos in India and South Africa from extinction. 

“People in Southeast Asia use rhino horn as a traditional medicine with a wide range of applications, including as a remedy for hangovers and other illnesses, including cancer,” said company CEO, Huyen Hoang. “So poachers are killing rhinos and selling their horns in an illegal global trading network where their street value is higher than gold. By providing an ethical alternative we aim to reduce the incentive for illegal poaching and save the rhinos from needless slaughter. Rhino horn is made of a single protein called keratin. We’ve teamed up with the world’s leading developer of keratin products, Keraplast Technologies, and using Replicine™ Functional Keratin® have produced a keratin protein powder that is biologically identical to the keratin from rhino horn. But unlike real rhino horn, Replicine™ Functional Keratin® is sustainably produced with no harm to animals and is proven in peer review medical publications to provide health benefits.” Dr Rob Kelly, Chief Scientific Officer of Keraplast Technologies added “our Replicine™ Functional Keratin® technology allows us to isolate particular keratin protein fractions, including pure intact keratin intermediate filament proteins. This is the exact type of keratin that makes up rhino horn provided in an identical manner to how people currently use it, satisfying this market demand in an ethical and sustainable way. Replicine™ Functional Keratin® is the basis of a range of health care and personal products all backed by strong scientific evidence.”

The company’s president, also named Huyen Hoang, said “The rhinos can only be saved from extinction by curbing demand for rhino horn in Southeast Asia. This means we need to find an ethical and sustainable alternative for rhino horn. We’ve done just that.” 

Rhinoceros Horn, LLC, is a Portland, Oregon based start-up company that provides a sustainable alternative to rhino horn. The company is a social enterprise whose mission is to save the endangered species of rhinos from extinction on Earth. Rhinoceros Horn is privately held in Portland, Oregon.

Keraplast Technologies LLC, a privately held company founded in 1996, is the world’s leading developer and manufacturer of keratin products. Headquartered in San Antonio, Texas, Keraplast manufactures Replicine™ Functional Keratin® wound care products with FDA and CE mark clearance for sale around the world, as well as a wide range of skin care, hair care and nutritional solutions using proprietary keratin technology.

Contact:

Huyen Hoang, Co-Founder & CEO
Rhinoceros Horn, LLC
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

www.rhinoceroshorn.com

503 473 1361
Huyen Hoang, Co-Founder & President

Rhinoceros Horn, LLC
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

www.rhinoceroshorn.com

503 317 7962

Dr Rob Kelly, CSO

Keraplast Technologies LLC

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

www.keraplast.com

210 591 8573

Posted in Company News |

San Antonio, Texas, USA, October 22, 2012. Keraplast Technologies announced  discovery of a new technology for gentle exfoliation of the skin. The world first approach uses Replicine™ Functional Keratin® particles as a physical exfoliant to gentle rub away dead cells from the skin surface. “The most significant innovations are often the most simple” said Dr Robert Allen Smith, MD, Keraplast Medical Director. He added “the outer layer of the skin is, of course, made of keratin protein so it seems perfectly natural to use little keratin washcloths, matched perfectly to the hardness of the skin, to rub away the dead cells. It has not been possible to do this before as the technology to isolate keratin particles in way that maintains the form and function of the keratin protein has not existed before. Replicine™ Functional Keratin® does this for the first time.”

Dr Rob Kelly, PhD, Chief Scientific Officer for the company commented “conventional physical exfoliants use particles that are too hard for the skin, such as ground walnut shells or plastic beads. This can lead to irritation and redness. Replicine™ Functional Keratin® particles are the perfect complement for the skin and remove dead cells leaving the skin refreshed with no irritation or redness. Enzymatic exfoliants dissolve away components of the skin to aid removal, but getting the right level of effectiveness is difficult. The use of keratin couldn’t be a more natural process.”

This first in class technology is available through high end retail outlets exclusively in the Retrospect skin care system in the form of Retropsect Microdermabrasion Cream. Visit www.retrospectusa.com for more details or purchase online at http://www.retrospectusa.com/retrospect-microdermabrasion-cream.html.

Keraplast Technologies LLC, a privately held company founded in 1996, is the world’s leading developer and manufacturer of keratin products. Headquartered in San Antonio, Texas, Keraplast manufactures Replicine™ Functional Keratin® wound care products with FDA and CE mark clearance for sale around the world, as well as a wide range of skin care, hair care and nutritional solutions using proprietary keratin technology. Keraplast believes in corporate social responsibility and strives to use its technology to make a difference. Keraplast works with the international charitable organisation DEBRA (www.debra.org) to make a difference to those living with epidermolysis bullosa.  

Contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it , 1-800-407-1783

www.retrospectusa.com

www.keraplast.com

Posted in Company News |

keragelT™ in a 5g tube size is now available in the US through Edgepark Medical Supplies. Edgepark is a distributor working across the US to provide a wide range of wound care product to the EB community. Accessing keragelT™ in the 5g tube size is an additional step in providing the best care available to the US EB community in the most convenient way possible, working with the experienced supplies and reimbursement teams at Edgepark. Please contact Edgepark Medical Supplies or call 1-800-321-0591.

Posted in Company News |

Access to keragelT™ in the US just got a lot easier through a partnership between Keraplast and National Rehab. National Rehab works across to the US to provide wound care, urological, ostomy and incontinence supplies as well as orthopedic products directly to patients. National Rehab then bills insurance plans for the supplies, thereby eliminating the need for patients to seek their own supplies from a durable medical equipment provider or pharmacy. keragelT™ is now available with a physician’s prescription from National Rehab by calling 1-800-451-6510, www.nationalrehab.com.

Posted in Company News |